Zacks Investment Research
06 Aug 2026, 23:31 UTC · 2h ago
Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Aug 2026, 23:31 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
BioMarin Pharmaceutical reported a quarterly EPS of $1.20, exceeding the Zacks Consensus Estimate of $0.96 by 25%. — A significant earnings beat typically triggers positive price movement as it indicates stronger profitability than analysts expected.
+0.60BioMarin reported quarterly revenue of $989.71 million, a 19.9% year-over-year increase and a 7.31% beat over consensus estimates. — Strong top-line growth and a revenue beat signal healthy demand and market expansion for the company's products.
+0.40BioMarin's reported EPS of $1.20 is a decline compared to the $1.44 reported for the same period a year ago. — The year-over-year decline in earnings suggests a contraction in profitability despite beating current analyst expectations.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company reported a revenue increase of 19.9% and a significant positive surprise in both revenue and EPS relative to consensus estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
